Pharmacokinetic Cross-Over Study of Pharmacy-Compounded Chenodeoxycholic Acid Capsules Compared to Authorized Capsules
Open Access
- 27 November 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (12) , 1525
Abstract
Purpose: The Amsterdam UMC pharmacy has been compounding chenodeoxycholic acid (CDCA) capsules for Dutch cerebrotendinous xanthomatosis patients since 2018. However, limited data are available on the pharmacokinetics and bioequivalence of therapeutic CDCA formulations. Methods: An open-label, single-center, randomized, two-period, two-sequence, cross-over study was conducted in 12 healthy volunteers to compare the pharmacokinetic profile of pharmacy-compounded CDCA capsules to that of the authorized CDCA product. Results: Both formulations reached peak plasma concentrations (tmax) at approximately 1 h post-dose. The mean AUC(0–6h) values were 262.4 (±69.4) µmol∙min/L for the compounded capsules and 248.0 (±78.1) µmol∙min/L for the authorized capsules, with a 90% confidence interval (CI) for the AUC(0–6h) ratio of 0.89–1.30, exceeding the accepted bioequivalence range of 0.80–1.25. The mean Cmax for the compounded formulation (2.96 ± 0.91 µmol/L) was significantly lower than that of the comparator product (4.42 ± 1.36 µmol/L; p = 0.0040), with a 90% CI for the Cmax ratio of 0.57–0.80, also outside the bioequivalence range. Conclusions: Overall, the pharmacy-compounded and authorized capsules demonstrate a comparable AUC(0–6h) and tmax. Bioequivalence could not be demonstrated, primarily due to high variation, a significantly lower Cmax, and an AUC(0–6h) ratio outside the accepted limits. These findings indicate that the compounded formulation results in reduced systemic peak exposure compared with the authorized product. However, given the high variation, a larger sample size would be needed to further investigate bioequivalence in future studies.Keywords
Funding Information
- Nationale Postcode Loterij
This publication has 10 references indexed in Scilit:
- Product development and quality of pharmacy compounded chenodeoxycholic acid capsules for Dutch cerebrotendinous xanthomatosis patientsFrontiers in Pharmacology, 2023
- Long-term MRI Findings in Patients With Cerebrotendinous Xanthomatosis Treated With Chenodeoxycholic AcidNeurology, 2022
- Bioequivalence data analysisTranslational and Clinical Pharmacology, 2020
- Chenodeoxycholic Acid: An Update on Its Therapeutic Applications2019
- The Pharmacology of Bile Acids and Their Receptors2019
- Dutch hospital makes own drug for rare condition after manufacturer hikes price to €170 000BMJ, 2018
- Rapid analysis of conjugated bile acids in plasma using electrospray tandem mass spectrometry: Application for selective screening of peroxisomal disordersJournal of Inherited Metabolic Disease, 1999
- Clinical Pharmacokinetics of Therapeutic Bile AcidsClinical Pharmacokinetics, 1996
- GeneReviews®1993
- Chenodeoxycholic AcidDrugs, 1981